anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thrombectomy plus local thrombolysis group - patients treated by mechanical thrombectomy mostly followed by catheter directed thrombolysis (CDT), or by pharmaco-mechanical thrombectomy (PMT) - combination of some form of mechanical disruption of the thrombus in conjunction with chemical lysis. Thrombolysis by alteplase 1mg/hour. Procedure followed by anticoagulation therapy.
Cardiac Rehabilitation (CR) is a Class I, Level A secondary prevention program that significantly reduces reinfarction and mortality rates in acute coronary syndrome (ACS) survivors. Yet, fewer than 30% of eligible cardiac patients participate in and adhere to CR programs in the United States. One promising avenue for increasing CR participation and adherence is a telehealth-enhanced hybrid CR (THCR) model that combines telehealth, clinic- and home-based CR. Several expert groups have strongly endorsed hybrid CR models that integrate telehealth (i.e., mobile apps, remote monitoring devices) because of their ability to offer the "best of both worlds" (i.e., in-clinic supervision/safety and at-home convenience) while also promoting real-time patient-provider communication and reimbursement as a telemedicine service. Despite its potential, the feasibility of and degree to which THCR improves adherence (e.g., # of completed sessions) and clinical outcomes (e.g., functional capacity) relative to traditional CR requires additional investigation. To understand the feasibility of THCR, the investigator will conduct a single center, two-arm, 1:1 parallel group randomized pilot study comparing THCR with traditional CR among ACS patients (N=40) to evaluate the feasibility (e.g., recruitment, adherence) of conducting an adequately powered randomized controlled trial.
Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
FIELD: veterinary. SUBSTANCE: new drug showing prolonged action is developed. Drug provides the curative effect at leptospirosis, pneumonia and bronchial pneumonia and other diseases in animals after twice or triple use at 72 hr interval. The base of drug proposed is a single dose of tetracycline (10000 U/kg animal mass) which has also polyvinylpyrrolidone, 1,2-propandiol and the solvent - dimethylsulfoxide used for prolonged effect of tetracycline and stimulation of immune response. EFFECT: enhanced effectiveness of preparation. 2 cl, 4 tbl
BACKGROUND AND OBJECTIVE: The identification of progression in patients with fibrosing non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs) represents an ongoing clinical challenge. Lung function decline alone may have significant limitations in the detection of clinically significant progression. We hypothesized that longitudinal changes of 6-min walk distance (6MWD) from baseline, simultaneously considered with measures of lung function, may independently predict survival and identifying clinically significant progression of disease.
METHODS: Forced vital capacity (FVC), diffusing lung capacity (DLCO) and 6MWD were considered both at baseline and at 1 year in a discovery cohort (n = 105) and in a validation cohort (n = 138) from different centres. The primary endpoint was lung transplant (LTx)-free survival.
RESULTS: Average follow-up was 3 years in both cohorts. Combined incidence of deaths and LTx was 29% and 21%, respectively. No collinearity and no strong correlations were observed among FVC, DLCO and 6MWD longitudinal changes. While age, gender and BMI were not significant, 6MWD decline ≥24 m predicted LTx-free-survival significantly and independently from FVC and DLCO declines, with high sensitivity and specificity, in both the discovery and the validation cohorts. Although FVC and DLCO declines remained significant predictors of LTx-free survival, 6MWD decline was more accurate than the proposed ATS/ERS/JRS/ALAT functional criteria. Results were confirmed after stratifying patients by baseline FVC.
CONCLUSION: Longitudinal declines of 6MWD are associated with poor survival in fibrosing ILDs across a wide range of baseline severity, with high accuracy. 6MWD longitudinal decline is largely independent from lung function decline and may be integrated into the routine assessment of progression.
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy affecting up to 13% of Americans; CTS is caused by compression of the median nerve in the carpal tunnel leading to nerve ischemia and symptoms of numbness, pain, and tingling. Treatment options depend on the severity of symptoms and range from noninvasive options (most commonly, steroid injections) to definitive surgical release of the compressed median nerve. Both non-invasive techniques and surgical intervention have their shortcomings; thus a novel approach for CTS treatment may be indicated.

Lipografting is an established, validated, and widely used technique of plastic surgeons that injects autologous fat to correct contour deformities. From observing these reconstructions, plastic surgeons have witnessed the regenerative properties of fat transfer, specifically delaying the affects of chronic radio-dermatitis. These clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, the fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors could stimulate nerve regeneration.
The study will demonstrate how a family-based navigator intervention combined with mHealth may lead to improved mental health treatment initiation and engagement among publicly-insured youth. Publicly-insured youth have high rates of mental health symptoms relative to youth in the community, and are disproportionately racial and ethnic minorities, only perpetuating disparities in this population's mental health access and engagement. The proposed project will develop and test a family-based navigator intervention, the Family Mental Health Navigator (FMHN), a natural fit for improving publicly-insured youth's mental health service and clinical outcomes. The study will start with identifying the feasibility and acceptability of the FMHN intervention. Then, the study will determine whether the FMHN intervention improves publicly-insured youth mental health treatment initiation and engagement. Finally, the study will characterize patterns of pre- and post-service outcomes along the behavioral health services cascade of care, to further evaluate the feasibility, acceptability, and preliminary impact of the FMHN model.
Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call "booster" intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period.
PURPOSE: A pharmaceutical composition and a health food containing a natural product extract for preventing or treating acute renal failure are provided to effectively prevent or treat acute renal failure and to suppress side effects caused from an anticancer agent such as cisplatin. CONSTITUTION: A pharmaceutical composition for preventing or treating acute renal failure contains a Trichosanthis semen extract or a fraction thereof as an active ingredient. The extract is prepared using water, C1-C4 alcohols, or a mixture thereof. The extract is prepared by ultrasonic wave extraction, room temperature extraction, hot water extraction, enfleurage extraction, reflux condensation extraction, or steam extraction. The fraction is a hexane fraction, an ethyl acetate fraction, a butanol fraction, or a water fraction. Acute renal failure is caused by an anticancer agent. A health food for preventing or treating acute renal failure contains the extract or the fraction as an active ingredient. [Reference numerals] (AA) Trichosanthes kirilowii (mg/kg)
A noise detection sensor structure provides hardware-assisted real-time artifact detection on a live bio signal of interest while that signal is being recorded. The structure is configured to detect and analyze the type of external noise, and to use information about the noise type (such as noise level, frequency range of noise, noise source) to improve signal quality and usability of the bio signal. Different algorithms can be used for each noise type detected. In some example cases, for instance, the structure is configured to at least one of extract noise from measurement signal, synchronize measurement with noise signal, change the software filter or analysis algorithm, change gain/filter settings of noise mitigation circuitry, and prompt user to assist as needed, based on the detected noise. Bad signal epochs can be discarded prior to recording, to efficiently use storage. Separate channel(s)/sensor(s) can be used, with different filtering/gain schemes, for noise detection.
PURPOSE: A composition containing human papilloma virus mutant and immunoadjuvant for preventing or treating cervical cancer is provided to induce HPV type 16 and 18 antigen-specific immune response and to treat tumor caused by HPV. CONSTITUTION: A fusion protein comprises: a fusion polypeptide which is derived from human papilloma virus type 16 and 18; a signal peptide for secreting polypeptides; and an immunoadjuvant. The signal peptide is tPa, HSV gDs or growth hormone secretion signal peptide. The signal peptide has an amino acid sequence of sequence number 2. The immunoadjuvant peptide is CD40 ligand, Flt3 ligand(fms-like tyrosine kinase 3 ligand), flagellin or OX40. The immunoadjuvant has an amino acid sequence of sequence number 3. A composition for preventing or treating diseases caused by human papilloma virus contains transformed host cell and crushed material thereof.
Acidic aluminium oxide is prepared by stirring aluminium oxide with carbon tetrachloride saturated with dry hydrogen chloride, filtering, rinsing with pure carbon tetrachloride and drying the residue at 50 DEG  C. under vacuum.  Acidic silica gel is prepared by suspending neutral silica gel in normal hydrochloric acid, filtering and drying the residue at 120 DEG  C.ALSO:The invention comprises (1) compounds of the formulae: <FORM:0965090/C1/1> <FORM:0965090/C1/2> <FORM:0965090/C1/3> (wherein R is a Hb (O acyl), a  alkyl b OH or a OH b  acetyl, the alkyl group containing at most 3 carbon atoms; and R1 is a Hb OH; and wherein the D 16 compounds may contain also a D 5 double bond) and esters thereof; and their preparation by treating compounds of the formulae: <FORM:0965090/C1/4> <FORM:0965090/C1/5> <FORM:0965090/C1/6> in an organic solvent with an adsorption agent under acid conditions until the evolution of nitrogen is complete; (2) 1-methyl-17a -vinyl and ethynyl- D 1-androsten-17b -ol-3-ones; (3) a process for the preparation of 1-methyl-17a -alkyl-D 1-androsten-17b -ol-3-ones wherein the 3-keto group of 1-methyl-D 1-androstene-3,17-dione is protected as by ketalization and either by Grignard reaction a 17a -methyl or -ethyl group is introduced by a similar method a 17a -ethynyl group is introduced and is then hydrogenated to the ethyl group, in either case the 3-keto group being subsequently reformed; and (4) a process for the manufacture of carboxylic acid esters of 1-methyl-D 1-androsten-17b -ol-3-one wherein the free 17b -ol is esterified with a carboxylic acid or a reactive derivative thereof. Suitable adsorption agents are aluminium oxide, silica gel, bleaching earth and ion exchangers.  Products may be esterified by customary methods.  The vinyl compound of (2) is prepared by process (3), the ethynyl group being only partially hydrogenated. Examples are given and a list of esterifying acids is provided. The preparation of 1-methyl-D 1-androsten-17b -ol-3-one by the process of the invention is also described.  Pyrazoline starting materials of the above general formulae are prepared by attachment of diazomethane to the corresponding a ,b -unsaturated keto steroids unsubstituted in b -position. 1- Methyl -D 1- androsten -3,17- dione 3-ethyleneketal is prepared by Oppenauer oxidation of 1-methyl-D 1-androsten-17b -ol-3-one 3-ethyleneketal, itself prepared by ketalization of the free ketone.  Esters of 1-methyl-D 1-androsten-17b -ol-3-one which are anabolic agents, may be dissolved in oleaginous solvents to prepare pharmaceutical injection solutions.
The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 10<SUP>8</SUP> and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.
Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
PURPOSE OF REVIEW: Sarcopenic obesity (SO), defined as the coexistence of excess fat mass and reduced skeletal muscle mass and strength, has emerged as an important cardiovascular risk factor, particularly in older adults. This review summarizes recent findings on the diagnosis, prevalence, health impacts, and treatment of SO.
RECENT FINDINGS: Growing evidence suggests SO exacerbates cardiometabolic risk and adverse health outcomes beyond either condition alone; however, the heterogeneity in diagnostic criteria and the observational nature of most studies prohibit the evaluation of a causal relationship. This is concerning given that SO is increasing with the aging population, although that is also difficult to assess accurately given wide-ranging prevalence estimates. A recent consensus definition proposed by the European Society for Clinical Nutrition and Metabolism and the European Association for the Study of Obesity provides a framework of standardized criteria to diagnose SO. Adopting uniform diagnostic criteria for SO will enable more accurate characterization of prevalence and cardiometabolic risk moving forward. Although current management revolves around diet for weight loss coupled with resistance training to mitigate further muscle loss, emerging pharmacologic therapies have shown promising results. As the global population ages, diagnosing and managing SO will become imperative to alleviate the cardiovascular burden.
A foaming effervescent bath composition is comprised of an effervescent base together with an anhydrous surfactant. The effervescent base may be sodium carbonate and an organic acid, or similar variations. The base is selected so as to provide a composition which has a high dissolution rate, of at least 0.4 g/sec. The product is designed so as to have a low density, not greater than about 1.0 g/cc. Surfactants that exhibit a high viscosity in the presence of low concentrations of salt give particularly good foaming performance. Other agents, such as a colorant, fragrance, humectant, or emollient, may be added.
Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA, which will include EMI prompts that they come up with at the end of the CLUE intervention (framed as "key takeaways"). After the two week period of EMA/EMI, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention.
Germline DNA testing using the next-gene-ration sequencing (NGS) technology has become the analytical standard for the diagnostics of hereditary diseases, including cancer. Its increasing use places high demands on correct sample identification, independent confirmation of prioritized variants, and their functional and clinical interpretation. To streamline these processes, we introduced parallel DNA and RNA capture-based NGS using identical capture panel CZECANCA, which is routinely used for DNA analysis of hereditary cancer predisposition. Here, we present the analytical workflow for RNA sample processing and its analytical and diagnostic performance. Parallel DNA/RNA analysis allowed credible sample identification by calculating the kinship coefficient. The RNA capture-based approach enriched transcriptional targets for the majority of clinically relevant cancer predisposition genes to a degree that allowed analysis of the effect of identified DNA variants on mRNA processing. By comparing the panel and whole-exome RNA enrichment, we demonstrated that the tissue-specific gene expression pattern is independent of the capture panel. Moreover, technical replicates confirmed high reproducibility of the tested RNA analysis. We concluded that parallel DNA/RNA NGS using the identical gene panel is a robust and cost-effective diagnostic strategy. In our setting, it allows routine analysis of 48 DNA/RNA pairs using NextSeq 500/550 Mid Output Kit v2.5 (150 cycles) in a single run with sufficient coverage to analyse 226 cancer predisposition and candidate ge-nes. This approach can replace laborious Sanger confirmatory sequencing, increase testing turnaround, reduce analysis costs, and improve interpretation of the impact of variants by analysing their effect on mRNA processing.
BACKGROUND: The incidence of infective endocarditis (IE) in patients undergoing redo mitral valve (MV) surgery was evaluated. The outcomes of all the patients and the patients' specific characteristics were recorded. The patients were analyzed to further the research of IE in this population.
METHOD: This was a retrospective review of patients admitted for redo MV surgery with a prospective follow-up of electronic medical records at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, from 2009 to 2019. Pre/intra/post-operative factors contributing to mortality, morbidity, and freedom of adverse events were analyzed.
RESULT: A total of 211 patients underwent redo MV surgery, and 41 patients (19.4%) had IE; and 51% of this subset of patients, 21 individuals, developed IE after the initial MV surgery. MV stenosis was moderate/severe in 50 patients. Furthermore, MV regurgitation was present in 89 patients. Multivariate analysis of the data revealed multiple factors influencing mortality: age, peripheral vascular disease, concomitant procedures, peripheral vascular disease, red blood cell transfusions, preoperative mechanical valves, and active IE. In-hospital Mortality was 10.9%. The one-, five-, and ten-year survival was 88%, 79%, and 69% across all patients.
CONCLUSION: Although redo MV surgery has acceptable outcomes; the presence of IE or concomitant procedures is a significant health detriment in these patients. Our study highlights the need for careful patient management and more in-depth research in this area to improve patient outcomes.
FIELD: medicine, cosmetology. SUBSTANCE: the present innovation deals with manufacturing cosmetic preparations with curativeprophylactic properties. The method includes extracting the product obtained out of medicinal leech subjected for preliminary starvation and freezing, moreover, frozen medicinal leech should be reduced, extracted with ethanol solution cooled up to +4 C at the ratio of 1:1 to obtain liquid phase. Obtained extract should be isolated against alcoholic constituent to obtain pH ranged within neutral values. The present method enables to obtain higher biological activity of target product obtained out of medicinal leech due to removing the capability for BAS complex-formation upon ballast and keeping BAS activity, bioenergomodulating properties among them. EFFECT: higher efficiency. 8 ex
Development of functional tricuspid regurgitation (TR) because of chronic mitral disease and subsequent heart failure is common. However, the effect of TR on clinical outcomes after transcatheter mitral valve replacement (TMVR) remains unclear. We aimed to evaluate the impact of baseline TR on outcomes after TMVR. This was a single-center, retrospective analysis of patients who received valve-in-valve or valve-in-ring TMVR between 2012 and 2022. Patients were categorized into none/mild TR and moderate/severe TR based on baseline echocardiography. The primary outcome was 3 years all-cause death and the secondary outcomes were in-hospital events. Of the 135 patients who underwent TMVR, 64 (47%) exhibited none/mild TR at baseline, whereas 71 (53%) demonstrated moderate/severe TR. There were no significant differences in in-hospital events between the groups. At 3 years, the moderate/severe TR group exhibited a significantly increased risk of all-cause death (adjusted hazard ratio 3.37, 95% confidence interval 1.35 to 8.41, p = 0.009). When patients with baseline moderate/severe TR were stratified by echocardiography at 30 days into improved (36%) and nonimproved (64%) TR groups, although limited by small sample size, there was no significant difference in 3-year all-cause mortality (p = 0.48). In conclusion, this study investigating the impact of baseline TR on clinical outcomes revealed that moderate/severe TR is prevalent in those who underwent TMVR and is an independent predictor of 3-year all-cause mortality. Earlier mitral valve intervention before the development of significant TR may play a pivotal role in improving outcomes after TMVR.